WHO ICTRP trial
A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the…
NL-OMON35852 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON35852 |
|---|---|
| Public title | A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40 mg Monotherapy. |
| Scientific title | A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40 mg… |
| Primary sponsor | Takeda |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Bulgaria;cs;Estonia;France;Germany;Italy;Netherlands ;Poland;Slovakia;Spain;Sweden;United Kingdom |
| Conditions | Grades 2 or 3 Hypertension/High blood pressure;10057166;Grades 2 or 3 Hypertension/High blood pressure |
| Interventions | Taking investigational product. ;Efficacy;Hypertension;Safety;Tak 491 |
| Registration date | Jul 13, 2012 |
| Target size | 28 |
| Secondary IDs | 2011-000220-16;NL36272.072.11 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: